Experimental treatment of chronic Trypanosoma cruzi infection in mice with 2-n-propylquinoline.

Abstract

It was reported previously that 2-n-propylquinoline was active against the epimastigote form of Trypanosoma cruzi. The effects of oral treatments with benznidazole and 2-n-propylquinoline were evaluated in Balb/c mice infected with T. cruzi chronically. The reference drug and 2-n-propylquinoline were administered 60 days post-infection for 30 days at 25 mg/mL. At 35 days post-treatment, the serological tests (ELISA) of the 2-n- propylquinoline-treated mice were significantly different from the controls (p = 0.01) and the benznidazole-treated mice (p = 0.03), while this was not the case at 85 days post-treatment. These results are encouraging for continuing the investigation of other analogues of 2-n-propylquinoline in experimental chronic Chagas' disease.

• Authors: H Nakayama, M E Ferreira, A Rojas de Arias, N Vera de Bilbao, S Torres, A Schinini, A Fournet
• Journal: Phytotherapy research : PTR (Phytother Res) Vol. 15 Issue 7 Pg. 630-2 (Nov 2001) ISSN: 0951-418X [Print] England
• PMID: 11746849 (Publication Type: Journal Article)
• Copyright: Copyright 2001 John Wiley & Sons, Ltd.

Chemical References

• 2-propylquinoline
• Nitroimidazoles
• Plant Extracts
• Quinolines
• Trypanocidal Agents
• benzonidazole

Topics

• Animals
• Chagas Disease (drug therapy)
• Chronic Disease
• Disease Models, Animal
• Enzyme-Linked Immunosorbent Assay
• Female
• Male
• Mice
• Mice, Inbred BALB C
• Nitroimidazoles (therapeutic use)
• Phytotherapy
• Plant Extracts (therapeutic use)
• Quinolines (therapeutic use)
• Rutaceae
• Trypanocidal Agents (therapeutic use)
• Trypanosoma cruzi (immunology, isolation & purification)